Antibody Clinical Development DNA Pharma Companies 
pharmaphorum
SEPTEMBER 8, 2022
It is a similar approach to that of another form of oncology treatment that is also experiencing a surge of interest, antibody-drug conjugates (ADCs). Big pharma has already noted its interest in the area, as seen in Novartis’ investments. Investment is flowing.
Drug Discovery World
OCTOBER 16, 2023
Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
OCTOBER 7, 2022
RA: How can the integration of industry and academia help streamline drug development? . TH : Increasingly, large pharma companies need scale, agility and access to academic partnerships to succeed. It is unsurprising that many pharma companies are increasingly keen to work with academia or academic spin-out.
The Pharma Data
OCTOBER 14, 2020
Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. VBL is currently advancing its lead anti-MOSPD2 candidate through IND-enabling studies.
The Pharma Data
DECEMBER 16, 2020
the company is exploring other ways to combat COVID-19. AstraZeneca is partnering with INOVIO and multiple universities to advance INOVIO’s innovative DNA-encoded monoclonal antibody (dMAb) technology. Recombinant monoclonal antibodies are designed to enhance the immune system’s ability to regulate cell functions.
Expert insights. Personalized for you.
104 
Let's personalize your content